LAGUNA NIGUEL, Calif., Nov. 28, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc.

LAGUNA NIGUEL, Calif., Oct. 3, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc.

NEW YORK, Sept.

Roche and Ipsen's investigational type 2 diabetes drug taspoglutide has demonstrated significant improvements in glucose control and weight loss after only eight weeks of treatment with a safety and tolerability profile that supports entry into Phase III.

NUTLEY, N.J., June 10 /PRNewswire/ -- Roche and Ipsen's investigational type 2 diabetes drug taspoglutide (R1583) has been shown to provide significant improvements in glucose control and weight loss after only eight weeks of treatment(1,2) with a safety and tolerability profile that supports entry into Phase III.